Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hemispherx Biopharma has executed an exclusive revenue sharing sales, marketing, distribution and supply agreement for Argentina with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA. Initial commercial target will be chronic fatigue syndrome in Latin America
Subscribe to our email newsletter
As per the agreement, GP Pharm will be responsible for gaining regulatory approval in Argentina for Ampligen, an experimental therapeutic, to treat chronic fatigue syndrome (CFS) in Argentina and for commercialising Ampligen for this indication in Argentina.
Further, Hemispherx has granted GP Pharm the right to expand rights to sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving certain performance milestones.
Hemispherx has also granted GP Pharm an option to market Alferon N injection, its FDA approved natural interferon, in Argentina and other Latin America countries as well. Under this agreement, the Hemispherx will manufacture and supply Ampligen to GP Pharm.
Thomas Kenwood Equels, executive vice chairman of Hemispherx, said: “Its Latin American Director, Jorge Braver, is a very experienced and effective pharmaceutical executive in Argentina and elsewhere in Latin America. I believe this relationship will eventually lead to opening large markets for Hemispherx’s platform technologies in Latin America.”
Braver, president of GP Pharm, said: “We are looking forward to expanding our relationship with Hemispherx by undertaking the commercialisation of Ampligen in Latin America. We are also excited to have the opportunity to market the FDA approved product, Alferon N injection, a natural interferon with a proven track record of safety and historically demonstrated exceptional anti-viral capabilities, throughout Latin America.”